Founded in 1992; offers biologics and liposome/LNP development and manufacturing, with an officially disclosed Austrian pharmaceutical manufacturing authorization.
AustriaFull profile →
mRNA / LNP · Companies
Matching companies load automatically. Browse 24 companies per page; expand filters to narrow the results.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
51 matching companiesShowing 25–48 / 51
Focuses on nucleic acid delivery platforms and intellectual property licensing; its LNP technology supports partner mRNA, RNA editing, and in vivo CAR-T programs.
CanadaFull profile →
Offers IVT mRNA-LNP development and manufacturing, with SMARTCAP capping and STLNP delivery technologies.
South KoreaFull profile →
The life science business of Germany's Merck KGaA offers mRNA, lipid, LNP, fill-finish, and testing services. It is separate from U.S.-based Merck & Co. / MSD.
GermanyFull profile →
Offers mRNA design, manufacturing, and LNP formulation, with disclosed partner work on tissue- and cell-targeted delivery.
NetherlandsFull profile →
Offers lipid- and polymer-based nonviral delivery systems, LNP/PNP formulation optimization, and manufacturing for mRNA and other nucleic acid payloads.
SpainFull profile →
Offers mRNA production services. In 2025 the company announced Belgian regulatory approval of an expanded mRNA manufacturing facility for late-stage clinical and commercial production.
BelgiumFull profile →
Founded in 2021, the company offers DNA, RNA, LNP/tLNP, analytical, and GMP manufacturing services for advanced-therapy CMC development.
Mainland ChinaFull profile →
Offers mRNA DNA templates, IVT and HiXCap capping, purification, LNP formulation, and aseptic fill-finish, and supplies nucleic acid raw materials.
Mainland ChinaFull profile →
GenScript's life science business offers IVT RNA and LNP-related services. Its ProBio subsidiary provides CGT CMC services including mRNA vaccines and nucleic acid drugs. Entity information uses GenScript group-level data.
United States / Mainland ChinaFull profile →
The Toyama site in Japan offers integrated GMP mRNA production, LNP formulation, and fill-finish. It is distinct from FUJIFILM Biotechnologies (formerly Diosynth).
JapanFull profile →
Offers mRNA development and manufacturing, with co-located mRNA, LNP, and fill-finish capabilities supporting RNA drug supply.
United StatesFull profile →
Offers LNP development and manufacturing for mRNA and other biological payloads, using processes including microfluidics, impingement mixing, filtration, and concentration.
GermanyFull profile →
Founded in 2007, the company offers cell-free enzymatic dbDNA templates for mRNA and other genetic medicines. This is an upstream template service, not equivalent to an mRNA-LNP drug product CDMO.
United KingdomFull profile →
Offers xRNA and LNP services, including mRNA drug substance, LNPs, and ATMP fill-finish. The current provider, brand, and manufacturing site require confirmation.
SwedenFull profile →
In 2023 Daiichi Sankyo announced Japanese approval of its DAICHIRONA (DS-5670) mRNA COVID-19 vaccine. The approved product should be evaluated separately from other newer programs.
JapanFull profile →
The company's first mRNA Japanese encephalitis vaccine, GBP560, entered Phase 1/2 trials in Australia and New Zealand. It is distinct from its existing non-mRNA vaccines.
South KoreaFull profile →
A historical partner page describes Stemirna's mRNA vaccine and nanolipid/polymer delivery R&D. The company's website was inaccessible during this review; current operations and clinical status remain unverified.
Mainland ChinaFull profile →
Yunxin Zhili is a Hangzhou-based service provider supporting process development, manufacturing, and CMC activities for advanced therapies. Its official materials describe plasmid and mRNA services spanning sequence and template preparation, RNA production, purification, LNP formulation, and testing, with targeted LNP development also listed. Manufacturing grade, project scale, timelines, and regulatory suitability require project-specific confirmation.
Mainland ChinaFull profile →
Levostar Biotech, based in Suzhou, supports nucleic acid and cell and gene therapy projects with plasmid services, RNA synthesis and delivery development, and analytical testing. Its mRNA offering includes sequence design, template construction, RNA production, and LNP formulation. The targeted LNP platform describes antibody conjugation and particle characterization. Manufacturing grade and suitability for a clinical regulatory submission must be confirmed for each project.
Mainland ChinaFull profile →
Develops circular RNA (oRNA) and LNP delivery. Its current LinkedIn page identifies it as a wholly owned Eli Lilly subsidiary, so it should not be treated as an independent private platform company.
United StatesFull profile →
An RNA and in vivo immune reprogramming platform developer; the website identifies it as a Bristol Myers Squibb company.
United StatesFull profile →
STX-001 is an intratumoral self-replicating mRNA treatment encoding IL-12. The company discloses a Phase 1 study and a broader programmable RNA platform.
United StatesFull profile →
Founded in 2019, the company develops mRNA, self-replicating RNA, and delivery platforms. In 2026 it reported early JCXH-213 results in two patients with ITP; these findings should be distinguished from formal registered-trial phases and independent validation.
Mainland ChinaFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.